Role of adjuvant chemotherapy in the management of stage IC ovarian granulosa cell tumors

摘要

ObjectiveThe aim of the present study was to investigate the patterns of use and prognostic significance of adjuvant chemotherapy (CT) for patients with stage IC ovarian granulosa cell tumors (GCTs).MethodsWe identified patients with stage IC GCTs diagnosed between 2004 and 2015 in the National Cancer Data Base (NCDB). Logistic regression was performed to identify variables independently associated with chemotherapy administration. Overall survival (OS) was evaluated for patients diagnosed between 2004 and 2014 following generation of Kaplan-Meier curves and compared with the log-rank test. A Cox model was constructed to control for known confounders.ResultsA total of 492 patients with stage IC GCTs were identified, of which 166 (33.7%) received CT. Tumor size >?=?10?cm (OR: 1.85, 95% CI: 1.21, 2.82) was independently associated with the administration of CT. There was no difference in OS between patients who did (n?=?145) and did not (n?=?282) receive CT,p?=?0.52; 5-yr OS rates were 93.7% and 91.6% respectively. After controlling for patient age (<50 vs ≥50?years), tumor size and performance of lymphadenectomy (LND), the administration of CT was not associated with a survival benefit (HR: 1.07, 95% CI: 0.52, 2.21).ConclusionsApproximately one in three patients with stage IC GCTs received CT in the NCDB, however CT was not associated with a survival benefit.